THB335 is a potent and selective oral small molecule inhibitor of wild type KIT (AAAAI-WAO 2025) - Feb 11, 2025 - Abstract #308; Pres time: Mar 1, 2025; 09:45 AM - 10:45 AM; Location: Convention Center, Ground Level, Hall A; "In the PCA model, THB335 oral administration resulted in a dose-dependent depletion of dermal mast cells achieving a 91.7% (p<0.0001) reduction with a concomitant reduction in cutaneous anaphylaxis of 86.5% (p<0.0001). Conclusions THB335 is a potent and selective inhibitor of wild type KIT that demonstrated efficacy in a rat model of passive cutaneous anaphylaxis."
Inflammation • CSF1R • FLT3 • PDGFRB
|
|
Michael Turner; Brian Chamberlain; Caitlin Kent; Chrisanthe Salemis; Gregg Keaney; Adrian Ray; Matthew Lucas
|